• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Pear Therapeutics closes $64m Series C round

January 9, 2019 By Sarah Faulkner

Pear Therapeutics logo updatedPear Therapeutics said this month that it closed a $64 million Series C round led by Temasek.

The Boston-based company plans to use its newly-acquired funds to support the global commercialization of its reSET prescription digital therapeutics and fund its clinical pipeline, as well as buy up additional assets.

Other investors in the round include Novartis (NYSE:NVS), 5AM Ventures and Arboretum Ventures. Pear landed new investors, too, including Blue Water Life Science Fund, Trustbridge Partners and a major diversified hedge fund.

“Pear ended 2018 with a number of major catalysts including commercial launch, product authorization, and pipeline advancement,” president & CEO Dr. Corey McCann said in prepared remarks. “Pear now kicks off 2019 with additional capital to bring PDTs to patients. We look forward to establishing PDTs as a widespread modality for directly treating a range of serious diseases.”

Earlier this week, Pear and Novartis division Sandoz kicked off the U.S. commercial launch of its digital therapy for people with opioid use disorder.

The two companies partnered in April last year on a commercial deal for the prescription digital therapeutics.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Business/Financial News, Featured, Funding Roundup, mHealth (Mobile Health), Pain Management Tagged With: peartherapeutics

IN CASE YOU MISSED IT

  • Elixir Medical reports sustained durability with bioadaptor compared to Medtronic stent
  • Senseonics closes public offering, private placement with Abbott
  • Embecta eyes shift from insulin delivery to broader medical supplies focus
  • Medtronic earns expanded CE mark for Prevail paclitaxel-coated balloon
  • Sequel Med Tech to pair automated insulin delivery system with Abbott’s future dual glucose-ketone sensor

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS